 | Up a level |
Best, Jan, Schotten, Clemens, Lohmann, Gregor, Gerken, Guido and Dechene, Alexander (2017). Tivantinib for the treatment of hepatocellular carcinoma. Expert Opin. Pharmacother., 18 (7). S. 727 - 734. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1744-7666
Lilienthal, Nils, Lohmann, Gregor, Crispatzu, Giuliano, Vasyutina, Elena 
ORCID: 0000-0001-9722-3419, Zittrich, Stefan, Mayer, Petra, Herling, Carmen Diana, Tur, Mehmet Kemal ORCID: 0000-0002-9259-6723, Hallek, Michael, Pfitzer, Gabriele, Barth, Stefan ORCID: 0000-0001-9589-653X and Herling, Marco
(2016).
A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death-Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells.
Mol. Cancer Ther., 15 (5).
S. 971 - 985.
PHILADELPHIA:
AMER ASSOC CANCER RESEARCH.
ISSN 1538-8514
Lohmann, Gregor, Schumacher, Bjoern and Herling, Marco (2017). Nucleotide excision repair as a targetable vulnerability in leukemia. Oncotarget, 8 (70). S. 114420 - 114422. ORCHARD PARK: IMPACT JOURNALS LLC. ISSN 1949-2553
Prinz, Christian, Vasyutina, Elena ORCID: 0000-0001-9722-3419, Lohmann, Gregor, Schrader, Alexandra, Romanski, Steffen, Hirschhaeuser, Christoph, Mayer, Petra, Frias, Corazon, Herling, Carmen D., Hallek, Michael, Schmalz, Hans-Guenther ORCID: 0000-0003-0489-1827, Prokop, Aram, Mougiakakos, Dimitrios and Herling, Marco
(2015).
Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden.
Mol. Cancer, 14.
LONDON:
BMC.
ISSN 1476-4598